Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York. more
Time Frame | BCLI | Sector | S&P500 |
---|---|---|---|
1-Week Return | 40.62% | -3.39% | -3.47% |
1-Month Return | 84.43% | -3.25% | -0.29% |
3-Month Return | -36.97% | -11.61% | 4.5% |
6-Month Return | -62.51% | -5.89% | 6.91% |
1-Year Return | -29.81% | 2.65% | 23.79% |
3-Year Return | -95.58% | 0.56% | 28.43% |
5-Year Return | -96.05% | 34.63% | 83.64% |
10-Year Return | -95.64% | 94.78% | 185.94% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | (366.00K) | - | - | - | - | [{"date":"2019-12-31","value":null,"profit":false},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | 366.00K | 219.00K | 260.00K | 285.00K | 265.00K | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":59.84,"profit":true},{"date":"2021-12-31","value":71.04,"profit":true},{"date":"2022-12-31","value":77.87,"profit":true},{"date":"2023-12-31","value":72.4,"profit":true}] |
Gross Profit | (732.00K) | (219.00K) | (260.00K) | (285.00K) | (265.00K) | [{"date":"2019-12-31","value":-73200000,"profit":false},{"date":"2020-12-31","value":-21900000,"profit":false},{"date":"2021-12-31","value":-26000000,"profit":false},{"date":"2022-12-31","value":-28500000,"profit":false},{"date":"2023-12-31","value":-26500000,"profit":false}] |
Gross Margin | 200.00% | - | - | - | - | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Operating Expenses | 23.00M | 31.68M | 24.54M | 24.82M | 21.17M | [{"date":"2019-12-31","value":72.6,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":77.45,"profit":true},{"date":"2022-12-31","value":78.34,"profit":true},{"date":"2023-12-31","value":66.83,"profit":true}] |
Operating Income | (23.00M) | (31.68M) | (24.54M) | (24.82M) | (21.44M) | [{"date":"2019-12-31","value":-2300100000,"profit":false},{"date":"2020-12-31","value":-3168400000,"profit":false},{"date":"2021-12-31","value":-2453900000,"profit":false},{"date":"2022-12-31","value":-2482200000,"profit":false},{"date":"2023-12-31","value":-2143900000,"profit":false}] |
Total Non-Operating Income/Expense | (504.00K) | (254.00K) | 164.00K | 1.09M | 4.24M | [{"date":"2019-12-31","value":-11.9,"profit":false},{"date":"2020-12-31","value":-6,"profit":false},{"date":"2021-12-31","value":3.87,"profit":true},{"date":"2022-12-31","value":25.74,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (23.25M) | (31.81M) | (24.46M) | (24.28M) | (17.19M) | [{"date":"2019-12-31","value":-2325300000,"profit":false},{"date":"2020-12-31","value":-3181100000,"profit":false},{"date":"2021-12-31","value":-2445700000,"profit":false},{"date":"2022-12-31","value":-2427700000,"profit":false},{"date":"2023-12-31","value":-1719200000,"profit":false}] |
Income Taxes | 252.00K | 127.00K | (82.00K) | (545.00K) | - | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":50.4,"profit":true},{"date":"2021-12-31","value":-32.54,"profit":false},{"date":"2022-12-31","value":-216.27,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Income After Taxes | (23.50M) | (31.94M) | (24.38M) | (23.73M) | - | [{"date":"2019-12-31","value":-2350500000,"profit":false},{"date":"2020-12-31","value":-3193800000,"profit":false},{"date":"2021-12-31","value":-2437500000,"profit":false},{"date":"2022-12-31","value":-2373200000,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Income From Continuous Operations | (23.25M) | (31.81M) | (24.46M) | (24.28M) | (16.63M) | [{"date":"2019-12-31","value":-2325300000,"profit":false},{"date":"2020-12-31","value":-3181100000,"profit":false},{"date":"2021-12-31","value":-2445700000,"profit":false},{"date":"2022-12-31","value":-2427700000,"profit":false},{"date":"2023-12-31","value":-1663200000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (23.50M) | (31.94M) | (24.38M) | (23.73M) | (17.19M) | [{"date":"2019-12-31","value":-2350500000,"profit":false},{"date":"2020-12-31","value":-3193800000,"profit":false},{"date":"2021-12-31","value":-2437500000,"profit":false},{"date":"2022-12-31","value":-2373200000,"profit":false},{"date":"2023-12-31","value":-1719200000,"profit":false}] |
EPS (Diluted) | (1.06) | (1.08) | (0.68) | (0.66) | (1.94) | [{"date":"2019-12-31","value":-106,"profit":false},{"date":"2020-12-31","value":-108,"profit":false},{"date":"2021-12-31","value":-68,"profit":false},{"date":"2022-12-31","value":-66,"profit":false},{"date":"2023-12-31","value":-194,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
BCLI | |
---|---|
Cash Ratio | 0.02 |
Current Ratio | 0.05 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
BCLI | |
---|---|
ROA (LTM) | -178.20% |
ROE (LTM) | -1121.90% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
BCLI | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 3.99 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | -2.99 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
BCLI | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 65.82 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | NM |
PEG | NM |
Brainstorm Cell Therapeutics Inc (BCLI) share price today is $2.1
Yes, Indians can buy shares of Brainstorm Cell Therapeutics Inc (BCLI) on Vested. To buy Brainstorm Cell Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in BCLI stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Brainstorm Cell Therapeutics Inc (BCLI) via the Vested app. You can start investing in Brainstorm Cell Therapeutics Inc (BCLI) with a minimum investment of $1.
You can invest in shares of Brainstorm Cell Therapeutics Inc (BCLI) via Vested in three simple steps:
The 52-week high price of Brainstorm Cell Therapeutics Inc (BCLI) is $11.89. The 52-week low price of Brainstorm Cell Therapeutics Inc (BCLI) is $1.05.
The price-to-earnings (P/E) ratio of Brainstorm Cell Therapeutics Inc (BCLI) is
The price-to-book (P/B) ratio of Brainstorm Cell Therapeutics Inc (BCLI) is 65.82
The dividend yield of Brainstorm Cell Therapeutics Inc (BCLI) is 0.00%
The market capitalization of Brainstorm Cell Therapeutics Inc (BCLI) is $12.83M
The stock symbol (or ticker) of Brainstorm Cell Therapeutics Inc is BCLI